QuatRx Pharmaceuticals Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM)
9/10/2009 8:14:54 AM
More...
|
QuatRx Pharmaceuticals Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
7/29/2009 8:46:26 AM
More...
|
QuatRx Pharmaceuticals Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
3/31/2009 8:24:05 AM
More...
|
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9/24/2008 8:59:43 AM
More...
|
QuatRx Pharmaceuticals Initiates Second Phase 3 Study of Ophena(TM) in Women With Postmenopausal Vaginal Syndrome
9/4/2008 8:56:19 AM
More...
|
QuatRx Pharmaceuticals Presents Results From Ophena(TM) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
6/16/2008 7:50:29 AM
More...
|
QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
1/4/2008 8:05:07 AM
More...
|
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM)
1/3/2008 7:50:12 AM
More...
|
QuatRx Pharmaceuticals Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8/22/2007 8:57:17 AM
More...
|
QuatRx Pharmaceuticals Closes $44 Million Series E Private Equity Financing
5/22/2007 11:25:57 AM
More...
|
|